Hormonal manipulation of benign prostatic hyperplasia
Authors:
- Ferenc G. RickFRFerenc G. Rick
- Seyed H. SaadatSSSeyed H. Saadat
- Luca SzalontayLSLuca Szalontay
- Norman L. BlockNBNorman L. Block
- Amir KazzaziAKAmir Kazzazi
- Bob DjavanBDBob Djavan
- Andrew V. SchallyASAndrew V. Schally
- 1 January 2013
- journal article
- review article
- Published by Wolters Kluwer Health in Current Opinion in Urology
- Vol. 23 (1) , 17-24
Abstract
We provide new viewpoints of hormonal control of benign prostatic hyperplasia (BPH). The latest treatment findings with 5-alpha reductase inhibitors (5-ARIs) finasteride and dutasteride, refined indications, efficacy, and safety are discussed and compared. We also discuss potential new 5-ARIs and other hormonal treatments. Finasteride and dutasteride have equal efficacy and safety for the treatment and prevention of progression of BPH. 5-ARIs are especially recommended for prostates greater than 40 ml and PSA greater than 1.5 ng/ml. Combination therapy is the treatment of choice in these patients, but with prostate volume greater than 58 ml or International Prostate Symptom Score of at least 20, combinations have no advantage over 5-ARI monotherapy. Updates on the recent developments on BPH therapy with luteinizing hormone-releasing hormone (LHRH) antagonist are also reviewed and analyzed. Preclinical studies suggest that growth hormone-releasing hormone (GHRH) antagonists effectively shrink experimentally enlarged prostates alone or in combination with LHRH antagonists. New 5-ARIs seem to be the promising agents that need further study. Preclinical studies revealed that GHRH and LHRH antagonists both can cause a reduction in prostate volume. Recent data indicate that prostate shrinkage is induced by the direct inhibitory action of GHRH and of LHRH antagonists exerted through prostatic receptors. The adverse effects of 5ARIs encourage alternative therapy.Keywords
This publication has 62 references indexed in Scilit:
- Combining Growth Hormone-Releasing Hormone Antagonist With Luteinizing Hormone-Releasing Hormone Antagonist Greatly Augments Benign Prostatic Hyperplasia ShrinkageJournal of Urology, 2012
- Antagonists of growth hormone-releasing hormone inhibit growth of androgen-independent prostate cancer through inactivation of ERK and Akt kinasesProceedings of the National Academy of Sciences, 2012
- New steroidal lactones as 5α-reductase inhibitors and antagonists for the androgen receptorThe Journal of Steroid Biochemistry and Molecular Biology, 2011
- Dutasteride Reduces Prostate Size and Prostate Specific Antigen in Older Hypogonadal Men With Benign Prostatic Hyperplasia Undergoing Testosterone Replacement TherapyJournal of Urology, 2011
- Antagonists of growth hormone-releasing hormone (GHRH) reduce prostate size in experimental benign prostatic hyperplasiaProceedings of the National Academy of Sciences, 2011
- Testosterone Therapy in Men with Androgen Deficiency Syndromes: An Endocrine Society Clinical Practice GuidelineThe Journal of Clinical Endocrinology & Metabolism, 2010
- A role for epithelial-mesenchymal transition in the etiology of benign prostatic hyperplasiaProceedings of the National Academy of Sciences, 2009
- The Relationship between Prostate Inflammation and Lower Urinary Tract Symptoms: Examination of Baseline Data from the REDUCE TrialEuropean Urology, 2008
- The Rationale for Inhibiting 5α-Reductase Isoenzymes in the Prevention and Treatment of Prostate CancerJournal of Urology, 2008
- Prostatic stromal cells derived from benign prostatic hyperplasia specimens possess stem cell like propertyThe Prostate, 2007